Product Description: Soforal LP is a fixed –dose combination tablet containing Ledipasvir and Sofosbuvir for oral administration.
Soforal LP is a fixed-dose combination of Ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and Sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in:
A. Adults with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
B. Adults with genotype 1 infection with decompensate cirrhosis, in combination with Ribavirin
C. Adults with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with Ribavirin.
|Product Name||: Soforal LP|
|Generic Name||: Sofosbuvir + Ledipasvir|
|Available Pack Size||: 6’s|
|Available Strength||: 400 mg + 90 mg|